Glaukos' Insider Sales: Diversification, Not Distress, Amidst Strong Growth

Related Articles

EQH Insider Sales: Diversification, Not Distress, Amidst Transformative Merger

3 months ago

Life360's Insider Sales: Diversification, Not Distress, Despite Stock Slide

3 months ago

Alignment Healthcare's Insider Sales Signal Diversification, Not Distress, Amidst Medicare Advantage Policy Headwinds

4 months ago

Arista Networks' Insider Sales: Diversification Amidst AI Growth Scrutiny

3 months ago

Category

You may also like

Stock News•3 weeks ago

Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

Glaukos reported that keratoconus patients maintained vision and corneal shape improvements three years after a single dose of its late-stage eye therapy, supporting the treatment's durability.

GKOS

Share

Stock News•3 months ago

Glaukos Corporation (GKOS) Q2 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) held its Q2 2026 earnings call. The transcript details management's discussion of quarterly financial results and business outlook.

GKOS

Share

Stock News•3 months ago

Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?

Glaukos CFO Alex Thurman sold 10,000 shares for ~$1.6M at $155/share on July 9, representing 19% of his total equity holdings.

GKOS

Share